Key Points
- Hellman & Friedman sold 6,088,371 shares at an average price of $28.37 on Dec. 18 for about $172.7M, cutting its ownership by 55.9% to 4,806,160 shares (SEC filing).
- Medline completed an IPO that raised roughly $6.26B, and two Mills family directors each bought ~2.58M shares at ~ $29 on Dec. 18, signaling insider confidence even as public float increased.
- Market signals are mixed: MDLN shares were up about 3.4%, while unusual options activity — ~20,689 put contracts (a ~326% jump) — suggests short‑term hedging or elevated volatility potential.
Medline (NASDAQ:MDLN - Get Free Report) major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business's stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Medline Stock Up 3.4%
NASDAQ:MDLN opened at $43.63 on Wednesday. Medline has a 1-year low of $34.89 and a 1-year high of $44.30.
Key Headlines Impacting Medline
Here are the key news stories impacting Medline this week:
- Positive Sentiment: Two Mills family directors executed very large purchases (~2.58M shares each at ~$29) on Dec. 18, signaling strong insider confidence in the company’s public debut. Read More. Read More.
- Positive Sentiment: Medline completed its IPO and implemented governance changes (Dec. 16), reducing public‑company transition risk and improving investor relations/governance visibility. Read More.
- Positive Sentiment: High‑profile positive media: Jim Cramer said he was “very impressed” with Medline’s IPO, which can attract retail and momentum flows. Read More.
- Neutral Sentiment: The IPO raised roughly $6.26B and delivered a large payday for the Mills family — important for capitalization and ownership structure but mixed for immediate float and liquidity dynamics. Read More.
- Negative Sentiment: Major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares at an average ~$28.37 (Dec. 18), materially reducing their stake and increasing float — a potentially negative supply signal. Read More.
- Negative Sentiment: Unusual options activity: ~20,689 put contracts traded (a ~326% jump vs. average), suggesting short‑term hedging or bearish positioning that could amplify volatility. (Reported Dec. 22)
Medline Company Profile
(
Get Free Report)
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
